1. Dynamic Co-evolution and Interaction of Avian Leukosis Virus Genetic Variants and Host Immune Responses
- Author
-
Xuan Dong, Fanfeng Meng, Tao Hu, Sidi Ju, Yang Li, Peng Sun, Yixin Wang, Wenqing Chen, Fushou Zhang, Hongqin Su, Sifei Li, He Cui, Junxia Chen, Shuzhen Xu, Lichun Fang, Huaibiao Luan, Zhenjie Zhang, Shuang Chang, Jianliang Li, Lei Wang, Peng Zhao, Weifeng Shi, and Zhizhong Cui
- Subjects
avian leukosis virus subgroup J ,genetic variants ,immune selective pressure ,co-evolution ,high-throughput sequencing ,Microbiology ,QR1-502 - Abstract
Subgroup J avian leukosis virus (ALV-J), a typical retrovirus, is characterized of existence of a cloud of diverse variants and considerable genetic diversity. Previous studies describing the evolutionary dynamics of ALV-J genetic variants mainly focused on the early infection period or few randomly selected clones. Here, we inoculated 30 specific-pathogen-free chickens with the same founder ALV-J stock of known genetic background. Six (three antibody positive and three antibody negative) chickens were selected among 15 chickens with viremia. Viruses were serially isolated in 36 weeks and then sequenced using MiSeq high-throughput sequencing platform. This produced the largest ALV-J dataset to date, composed of more than three million clean reads. Our results showed that host humoral immunity could greatly enhance the genetic diversity of ALV-J genetic variants. In particular, selection pressures promoted a dynamic proportional changes in ALV-J genetic variants frequency. Cross-neutralization experiment showed that along with the change of the dominant variant, the antibody titers specific to infectious clones corresponding to the most dominant variants in weeks 12 and 28 have also changed significantly in sera collected in weeks 16 and 32. In contrast, no shift of dominant variant was observed in antibody-negative chickens. Moreover, we identified a novel hypervariable region in the gp85 gene. Our study reveals the interaction between ALV-J and the host, which could facilitate the development of vaccines and antiviral drugs.
- Published
- 2017
- Full Text
- View/download PDF